1. Generics Bulletin
  2. >>Business
  3. >>Deals

Sandoz Chief Looks To Build On Recent Deals

CEO Richard Saynor Offers The Latest On Anti-Infectives, Generics And Biosimilars

 
• By Dave Wallace

With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.

Jigsaw pieces color white
Sandoz is integrating a number of recent deals • Source: Shutterstock

In the wake of a series of deals and acquisitions, Sandoz is looking to integrate fresh assets and build on its current business with further investments ahead of some key launches in 2023, CEO Richard Saynor has set out in the second part of an exclusive three-part interview.

Despite Sandoz being in the midst of preparations to be spun off from parent firm Novartis (see sidebar), there has been no slowdown in deal-making for the generics and biosimilars company, with the firm kicking off 2023 by announcing a technology licensing deal with Korea’s Alteogen for biosimilars as well as an agreement to acquire worldwide rights to the Mycamine (micafungin) antifungal brand from Astellas

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.